← All trials
NCT02560441
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 1, 2015
- Primary completion
- Sep 1, 2017
- Completion date
- —
- First posted
- —
- Last posted
- —
- Enrollment
- 200
- Arms / groups
- 3 / —
- Source
- AACT · pre-existing
Sponsors
- Chinese Academy of Medical SciencesLead sponsor
- Xuzhou Medical UniversityCollaborator
- Shantou UniversityCollaborator
- Southern Medical UniversityCollaborator
- Shandong UniversityCollaborator
- Guangxi Medical UniversityCollaborator
- Zhangzhou Municipal Hospital of Fujian ProvinceCollaborator
- Shanxi Medical UniversityCollaborator
- Dalian Medical UniversityCollaborator
- Tianjin Medical UniversityCollaborator
- China Medical UniversityCollaborator
- People's Liberation Army of ChinaCollaborator
- Hebei UniversityCollaborator
- Chinese Academy of Medical SciencesReponsible party - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.